115 results about "Lung infection" patented technology

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.

The presence of a pathologic process in a lung of a mammal is detected by applying exhaled gas of a mammal to an electronic nose (12). Data derived from the electronic nose (12) is used to determine whether a pathologic process is present in the lung of the mammal. The pathologic process may also be a lung infection such as pneumonia. Also, a mammalian fluid sample obtained from the sinus or nose is applied to an electronic nose (12) to determine if the fluid sample contains significant amounts of cebrospinal fluid.

A compound florfenicol injection for treating the pneumonia and bacterial lung infection of pig is prepared from florfenicol, doxycycline, dimethyl formamide, magnesium dichloride, polyvinyl pyrrolidone, trimethoprim and propanediol. Its preparing process is also disclosed.

The invention discloses a traditional Tibetan medicine for treating cough and a preparation method thereof. The traditional Tibetan medicine for treating the cough is composed of active ingredients or is composed of the active ingredients and pharmaceutically acceptable auxiliary materials, wherein the active ingredients are prepared from liquorice, phyllanthus emblica, common vladimiria root, sea buckthorn paste, cordyceps sinensis and bulbus fritillariae cirrhosae in certain weight proportion. The traditional Tibetan medicine for treating the cough disclosed by the invention can be preparedinto any common oral administration dosage form. The traditional Tibetan medicine for treating the cough disclosed by the invention has the effects of relieving cough and reducing sputum, clearing throat and relieving sore throat, invigorating blood circulation and removing blood stasis, moistening lung and diminishing inflammation. The traditional Tibetan medicine for treating the cough disclosed by the invention is used for treating cough, vomiturition, thick and excessive phlegm, bronchitis, lung infection and throat fatigue, hoarseness, chronic pharyngitis and asthma which are caused by cold.

Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Administration of SP-D protein or fragments thereof is useful for the prevention or treatment of sepsis or lung infection.

The invention provides a multifunctional nasal feeding tube and a nasal feeding system. The multifunctional nasal feeding tube is characterized in that a tube body of the nasal feeding tube is internally provided with a non-return valve; an airbag is arranged at the outer side of the tube body of the nasal feeding tube; the airbag is connected with a pressurizing airbag through an air guiding tube. The non-return valve can be used for preventing nutrient solution in the nasal feeding tube from reflowing; the airbag at the outer side of the tube body of the nasal feeding tube is inserted in the position of stomachus cardiacus; after the inflation of the pressurizing airbag, the situation that gastric contents at the outer side of the nasal feeding tube are sucked into a lung by mistake due to reflow can be effectively prevented. According to the multifunctional nasal feeding tube and the nasal feeding system, aspiration complications caused by enteral nutrition support therapy through nasal feeding can be prevented specifically; the lung infection, severe pneumonia, even asphyxia caused by aspiration progress are effectively reduced, and the death rate is lowered. The multifunctional nasal feeding tube and the nasal feeding system can be widely suitable for popularization and application of clinical enteral nutrition support therapy. Moreover, the nasal feeding tube is further provided with an injector joint and a drug administration joint, so that the drug administration operation is conveniently performed on a patient who cannot swallow drugs independently. A feeding material supply system is arranged in the nasal feeding system, nutrients can be continuously fed to the patient after the connection with the nasal feeding tube, and the feeding efficiency is improved.

The invention discloses a method for detecting pathogenic bacteria of pulmonary infection by a visualized gene chip, comprising the following steps: S1 determining the spectrum of pathogenic bacteria of pulmonary infection based on clinical practice; S2 making the detection target according to the specific gene of the bacteria; S3 designing general primers and probes S4 chip preparation; S5 target gene amplification; S6 chip hybridization and washing; S7 gene chip visual detection; S8 optimization conditions, establishment of methods; S9 clinical verification; S10 comparison with bacterial culture; Chip detection. Beneficial effects of the present invention: realize rapid, sensitive, and high-throughput detection of important pathogenic microorganisms of common clinical respiratory infection flora, provide evidence for clinical disease diagnosis and anti-infection treatment of acute and severe respiratory infectious diseases; provide emergency, prevention and control Provide effective and efficient screening means and methods.

The invention provides a lung-targeting ceftiofur microsphere and a preparation method thereof, aiming at solving the problems that less medicine can reach the target part in the prior art, so that a great deal of medicine is wasted, the treatment effect is not remarkable, the toxic and side effect of the medicine is increased, and the probability of generating drug resistance is high. The technical scheme comprises: the microsphere takes ceftiofur as raw material and PLA as carrier material, and the weight ratio between the ceftiofur and the PLA is 1:0.5-10. The invention also provides the method for preparing the microsphere by emulsification. The microsphere prepared by the method has round appearance and shape, even grain fineness distribution, the average grain diameter of about 20mu m and higher medicine-loading rate. The microsphere can be used for treating lung infection of livestock and poultry with high effect, and leads the ceftiofur to be made into the lung-targeting microsphere so as to improve the concentration of the medicine at the lung tissues of animals and lead the medicine effect to be more remarkable, thus achieving the aims of slow release, long-term effect and target.

A composite medicine in the form of injection or orally taken solid or liquid for treating asthmatic chronic bronchitis, acute bronchal asthma, lung infection, pneumonia, pneumonectasis, cardiogenic asthma, pulmonary tuberculosis, silicosis, etc is prepared from indianmulberry root or its extract and picrorhiza rhizome or its extract. Its preparing process is also disclosed.

The invention provides lung targeting ceftiofur microsphere and a preparation method which can solve the problems the prior art that few positions reach a target, so that a lot of medicine is wasted, the therapical effect is insignificant, the toxin and side effect of the medicine are improved and the chance of leading to medicine resistance is great. The technical scheme is as follows: the microsphere takes ceftiofur as the raw material, PLGA as the carrier material, and the weight ratio of ceftiofur to PLGA is 1:1 to 1:50. The invention also provides a method for preparing the microsphere through an emulsion process. The microsphere can treat the lung infection of animals with high efficiency; and the ceftiofur is prepared into lung targeting microsphere, thereby improving the concentration of the medicine in the animal lung tissue, so that the therapical effect is more significant. The microsphere prepared through the method has the advantages of very good morphology and very strong controllable particle size, can achieve high lung targeting property by optimizing the particle size, so that the particle size of more than 90 percent of microsphere is 7 to 30mu m, the encapsulation rate of the microsphere is more than 65 percent, the drug loading can reach 8 to 24 percent, and the microsphere has better releasing effect.

The invention discloses a medicine for treating cough. The effective ingredients contain Radix Glehniae, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Folium Mori, Radix Glycyrrhizae, Radix Trichosanthis and Semen Lablab Album seven drugs. The effective components in the prescription are fully utilized through the preparation process in which parts of the drugs are extracted by ethanol and parts of the drugs are extracted by water, at the same time, the effective components are purified through effective preparation technology. The clinical tests show that the invention has more than 90 percent of cure rate to URI, acute and chronic bronchitis, and to cough and phlegm and hyperpnea and breathlessness caused by lung infection. The invention is an external-use paste which has the advantages of accurate effect, convenient carrying, functions of clearing lung and removing phlegm and relieving cough and asthma, and evident effect on treating cough.

The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.

The invention relates to a slow-release lung targeted microcapsule preparation of florfenicol with a good targeted function and a slow-release function, and a preparation method thereof. The capsule selects gelatin, ethyecellulose or arabic gum as a material, and the florfenicol micropowder as a capsule core, wherein the mass ratio of the material to the capsule core is controlled to be (1:1)-(1:2); and the particle size of the florfenicol micropowder is controlled to be 2-10 mu m. The preparation method comprises the following steps: swelling the capsule material in water in advance, wherein, the weight concentration is controlled to be 10-20%; evenly suspending the florfenicol micropowder into an aqueous solution of the capsule material; manufacturing a microcapsule through a spray drying method, wherein, the air intake temperature is controlled between 80 and 110 DEG C, the air outlet temperature is controlled between 110 and 130 DEG C, and the spray flow is 0.3-0.6 litre per minute; and performing spray drying to prepare the microcapsule preparation which has the lung targeted function, can lead drugs to enrich into lung tissues, has better curative effects on lung infection, has a long-acting and slow-release function, decreases the times of drug administration, lowers the quantity of labor of cultivation workers, and lightens the stress reaction of animals.

The invention relates to application of chloroquine and chlorpromazine to preparation of drugs for treating and preventing lung infection and injuries, in particular to application of the chloroquine, the chlorpromazine, derivatives of the chloroquine and the chlorpromazine, mixture of the chloroquine and the chlorpromazine, and drug compositions containing the chloroquine or the chlorpromazine to the preparation of drugs for treating and/preventing lung infection and injuries caused by influenza viruses to mammals including human.

The invention discloses a preparation method of a lung-soothing concentration pill. The preparation method comprises the following steps: taking hempleaf groundsel herb as raw materials, adding water to soak the hempleaf groundsel herb, performing extraction through an ultrasonic extraction tank, and merging the extracts for decoction, filtering and concentration to obtain an extractum; drying and crushing extractum to sieve by a 100-mesh sieve, so as to obtain hempleaf groundsel herb extractum powder; mixing with starch, microcrystalline cellulose and sodium carboxymethyl starch to form mixture powder; preparing the concentration pill by a centrifugal coating palletizing machine. The concentration pill has the benefits of reducing fever, eliminating phlegm, relieving cough and relieving asthma, can be used for lungs infection, chronic bronchitis, asthmatoid bronchitis, acute respiratory tract infection and the like. According to the invention, as ultrasonic extraction is adopted, the dissolving-out amount of effective component of materials to be extracted can be improved in unit time, and the prepared concentration pill is high in effective component content, small in taking dose and small in local irritation.

The invention provides a method for evaluating a lung infection medicine. In the method, an acinetobacter baumannii lung infection model is constructed by an ultrasonic atomization method, bacterium quantitative culture and pathological inspection are carried out, and comprehensive evaluation is carried out according to various indexes, such as general situations, pathological changes, lung bacterium number changes and the like, of rats at different infection time. The method for evaluating the medicine, which is provided by the invention, has the advantages of strong practicability, very high repeatability, reliability, applicability and controllability of the model, very small difference between model rats, good stability of the model, high similarity degree with a clinical pathogenic process, high model formation speed and the like, has the most pivotal advantage of simple operation of the model constructed by the method, can carry out batch operation simultaneously and provides a basis for researching on acinetobacter baumannii lung infection pathogenic mechanism and sieving treating medicines.

The invention discloses a Chinese medicine preparation capable of curing pediatric asthmatic pneumonia. The asthmatic pneumonia belongs to the category of Chinese medicine 'pneumonia with dyspnea and cough', the pathogenesis includes that wheezing and coughing are probably caused by pathogen blocked in a lung, lung infection, heat transmission, phlegm production and reversed flow of phlegm along with air. Therefore, by means of the Chinese medicine preparation capable of curing the pediatric asthmatic pneumonia, the Chinese medicine of marsdenia tenacissima, callianthemus, small lilac, crepis phoenix, radix tetrastigme, vernonia cinerea, ardisa japonica blume, gynostemma pentaphyllum, cortex mori radicis, eriobotrya seguinii, ephedra, lanjiang lily bulb, aster, perny false fairybells rhizome, lotus seeds and gordon euryale seeds, and water are decocted into soup decoction to be drunk by a patient. By means of the clinical test of the hospital, the overall effective rate reaches 98.3%, the curing effect is stable, and the side effect is small.

A composite medicine in the form of injection or orally taken solid or liquid for treating asthmatic chronic bronchitis, acute bronchal asthma, lung infection, pneumonia, pneumonectasis, cardiogenic asthma, pulmonary tuberculosis, silicosis, etc is prepared from epimedium or its extract, picrorhiza rhizome or its extract, and indianmulberry root or its extract. Its preparing process is also disclosed.

The invention discloses an anti-infection nasal vestibule covered stent and a preparation method and application thereof, the nasal vestibule covered stent comprises a stent body, the shape and size of the stent body are matched with the shape of a nasal vestibule; and a covering film, wherein the covering film is compounded on the stent body. The stent body has a shape memory function and is well matched with the form structure of the nasal vestibule of a human body. The covering film is composed of at least one fiber layer, and the aperture of the fiber layer is gradually reduced from the lowermost layer of the lower covering film to the uppermost layer of the upper covering film in a gradient mode. The nasal vestibule covered stent provided by the invention can achieve gradient filtration of gas inhaled into a human body through a nose, and achieves the purpose of preventing bronchial, microbronchial and pulmonary infection of an artificial trachea or tracheal stent transplantation patient. The stent is simple in structure, convenient to manufacture, attractive in application and remarkable in anti-infection effect, medicine carrying and medicine releasing of the covered stent can be achieved, and the stent has multiple additional function attributes.